Institutional Biosafety Committee
Nov-14-2025

Location: Microsoft Teams

Member Roster: Brad De Pons (IBC Chair), Sonia Bardy (IBC Vice Chair), Zac Driscoll, David Frick, Andrew Kuzma, Diane Lindsley, Dean Nardelli, Jenny Nemke, Heather Owen

Additional Attendees:

Non-Voting members

Melody Harries attended 1:30-2:40pm

Guests:

Nathan Schneiderman attended 1:30-2:40pm
Aimee Hamilton attended 1:30-2:40pm
Melissa Spadanuda attended 1:32 -2:40
Ching-Hong Yang attended 1:32- 1:43pm
Priyatha Premnath attended 1:56-2:02pm
Madhusudan Dey attended 2:03-2:28pm

1. Call to Order

The meeting was called to order at 1:32pm.

2. Announcements

- BSO Updates
  - Spill, Exposure, & Near Miss Reports: None

3. Protocol Reviews

Renewals

Closed Session Requested Pursuant to Wis. Stat. sec. 19.85(1)(e)

1:34pm: Motion to go into closed session pursuant to Wis. Stat. Sec. 19.85(1)(e): Deliberating or negotiating the purchasing of public properties, the investing of public funds, or conducting other specified public business, whenever competitive or bargaining reasons require a closed session.

Motion made by Dean Nardelli and seconded by Diane Lindsley. Unanimous approval.

1:35: Motion to invite guests Nathan Schneiderman, Aimee Hamilton, Melissa Spadanuda, and Ching-Hong Yang. Motion made by Heather Owen and seconded by Sonia Bardy. Unanimous approval.

Protocol Number: B20.004

Principal Investigator	Yang, Ching-Hong
Protocol Number	B20.004
Title	Isolation and Identification of Bioactive Bacteria in Large-Scale Culture
NIH Guidelines Section	III-D-6
Short Summary	[Tabled from October meeting] Previously approved protocol requesting a 3-year renewal. The aims of the protocol are to isolate and identify bioactive compounds that can either inhibit the growth of plant or animal pathogens or specifically inhibit type 3 secretion system of gram-negative bacteria. Bacteria are isolated from soil obtained in Wisconsin and other states and are identified through 16s rRNA results.
Materials / Agents	Bacteria
Inspection Status	Biosafety inspections are up to date
Training Status	Biosafety trainings are up to date
Proposed BSL(s)	BSL-1
Modifications added:	None

Discussion of Protocol B20.004

Ching Hong Yang attended the discussion from 1:35-1:43 pm

The PI presented an overview of the study. This study is funded by a USDA grant. Previously, the investigator isolated microbes from soil and identified them through 16s genotyping. Bacteria that produce bioactive compounds that prevent disease in specific food crops have been identified. The investigator is using a 30L fermenter to create and purify the bioactive compounds of interest. The compounds produced are analyzed in collaboration with Iowa State University. These bioactive compounds are used in Florida, Michigan, California, and Iowa. While he does not currently anticipate analyzing stored soil bacteria samples to identify new soil isolates, he would like to retain the option to do so.

The PI left for the IBC discussion and vote. The committee agreed that the current work was appropriate to conduct at BSL-1, but felt that if new compounds were isolated, this work should be conducted at BSL-2 due to the unknown risk of unidentified materials that may be present. The committee determined that if the PI wants to begin working with the stored soil samples, he must first submit an amendment or new protocol to work at BSL-2.

1:55pm: Motion made by Sonia Bardy, seconded by Heather Owen to approve as submitted, with the stipulation that an amendment must be submitted prior to resuming soil analysis.

For: 9
Against: 0
Abstain: 0

1:55pm: Motion by Diane Lindsley, seconded by Sonia Bardy to return to open session. Unanimous approval.

Protocol Number: B20.013

Principal Investigator	Premnath, Priyatha
Protocol Number	B20.013
Title	Role of cell cycle regulators in bone healing
NIH Guidelines Section	F (exempt)
Short Summary	The goal of this investigation is to improve bone healing in diseased or aged patient populations through temporary inhibition of cell cycle regulators (p21, E2F1) using a small molecule (UC2288). It is hypothesized that using the small molecule UC2288 to temporarily inhibit p21 will lead to the recruitment of chondrocytes to a healing callus and increase bone formation. The investigation will define the efficacy of the small molecule drug UC2288 to temporarily inhibit p21 at the site of bone healing in aged wildtype mice.
Materials / Agents	Animals
Inspection Status	Biosafety inspections are up to date
Training Status	Biosafety trainings are up to date; bloodborne pathogens training is expired for one staff member.
Proposed BSL(s)	BSL-2
Modifications added:	In this renewal, personnel will be updated. The protocol otherwise remains the same.

Discussion of Protocol B20.013

Priya Premnath attended the discussion 1:56-2:02 pm.

The PI provided an overview of the protocol and shared the progress to date. The research has progressed well, and no changes to the current procedures or materials are requested aside from personnel updates. The committee questioned the disposal of blood, as the lab-specific biosafety manual described disposing of human and animal blood into the sanitary sewer. The PI clarified that human blood is not disposed into the sewer, and typically only small amounts of animal blood are generated which can be easily absorbed with a paper towel.

The committee returned to discussion of this protocol at 2:34. The committee further discussed proper practices for disposal of blood, and determined that the protocol should be amended to clarify that human blood is not being dumped into sinks. Large quantities of animal blood should not be flushed down the drain without being sanitized.

2:37pm: Motion made by Jenny Nemke, seconded by Sonia Bardy, to approve pending modifications to update the lab-specific biosafety manual disposal practices for blood, specifying an emergency contact who is not affiliated with the study, completion of bloodborne pathogens training for all staff,

and updating the dates for biosafety and lab safety inspections, biosafety cabinet certification, and fume hood testing.

For: 9
Against: 0
Abstain: 0

Protocol Number: B20.012

Principal Investigator	Dey, Madhusudan
Protocol Number	B20.012
Title	Working with mammalian cells in Lapham Hall Room No 446
NIH Guidelines Section	F (exempt)
Short Summary	The investigators are requesting a 3-year renewal to protocol B20.012 with the addition of MCF10A and SfP human cell lines. The investigator's goal is to identify possible drug targets in unfolded protein response signaling pathways (UPR). The aim of the study is to understand how cells synthesize protein, how proteins fold, and how cells adapt to endoplasmic reticulum stress.
Materials / Agents	Human or NHP Blood, Cells, Tissue, and/ or Fluids, Plasmids, Recombinant DNA/ Synthetic Nucleic Acid Molecules
Inspection Status	Biosafety inspections are up to date
Training Status	Biosafety trainings are not up to date for lab staff
Proposed BSL(s)	BSL-2
Modifications added:	I am adding the MCF10A and Sf9 cell lines. Cell lines: HEK293: Human Embryonic Kidney (HEK) 293 is a cell line. MCF10A: Human mammary epithelial cell line – non-tumorigenic epithelial lines. Sf9: Insect cell line for large scale protein expression and purification

Discussion of Protocol B20.012

Madhusudan Dey attended the discussion 2:03-2:28pm.
The PI provided an overview of the study and the requested changes associated with the renewal. The investigators are attempting to identify possible drug targets that prevent misfolding of proteins. Previously, the investigators used non-pathogenic E. coli to express human proteins, but the protein product was inactive and could not be used.

The investigators are adding the insect cell line Sf9 that produces the protein of interest in large amounts. The insect cell line Sf9 is used because it produces biologically active human protein. An insect virus is used to insert a plasmid into the Sf9 cells that produces the pk1 gene. The Sf9 cell line is then grown on media. The pk1 protein is expressed and purified from the Sf9 cell line. The investigators purify the proteins from the cells for further analysis. Once purified, the investigators study pk1activity in the HEK 293 and the MCF10A cell lines by transfecting both cell lines with the pk1 protein to investigate the action of the protein. All cell lines used for the protocol are non-pathogenic.

In response to a committee member's question about training practices, the PI clarified that he primarily trains lab staff, but graduate students who have sufficient experience in the lab may also provide training. When questioned about disinfection practices, the PI stated that he does not use bleach, only ethanol.

The PI left for the final discussion and vote. The IBC discussed whether ethanol alone was sufficient and determined that bleach or another disinfectant needed to be used prior to using ethanol.

The committee also discussed the protein purification process. The protocol did not adequately describe the process, but the committee was comfortable with the PI's verbal description of his procedures. These additional details that were relayed verbally should be incorporated in writing into the protocol.

2:34pm: Motion made by Heather Owen, seconded by David Frick, to approve pending modifications to clean surfaces with bleach or other disinfectant prior to ethanol, provide more details about the protein purification process, clarify laboratory training procedures, and complete biosafety training for staff whose training has expired.

For: 9
Against: 0
Abstain: 0

4. Notifications

Administrative Approval of Protocol Amendments

Study Number	Title	PI	NIH Section / Containment Level	Note
B24.004	LRRK2 cell biology and Parkinson's disease	An-Phu Tran	D-1, D-2, D-3, D-4, E-1, F / BSL-2	Amendment to add new plasmids GFP-ATG8(416)/GFP-AUT7(416), lentiCRISPR v2, and pCDF-Leup, approved administratively.

Approval of Minor Modifications on Renewals

Study Number	Title	PI	NIH Section / Containment Level	Note
B20.006	"fish-boom-ba: zebrafish	Kurt Svoboda	D-4 / BSL-2	3-year renewal reviewed by full committee

	environmental toxicology screening platform"			

5. Old Business

1. Approve October 10, 2025 Meeting Minutes

2:40pm: Motion made by Diane Lindsley, seconded by Heather Owen, to approve meeting minutes from the Institutional Biosafety Committee meeting on October 10, 2025.

For: 8
Against: 0
Abstain: 1 (Jenny Nemke)